Tri Glynase 2 mg Tablet (10 Tab)

Glimepiride, an antidiabetic sulphonylurea, reduces blood glucose by stimulating the insulin release from pancreatic ß-cells and decreases glucose output from the liver. It also increases insulin sensitivity at peripheral target sites.

Metformin is a biguanide antihyperglycaemic agent which improves glucose tolerance by lowering both basal and postprandial plasma glucose. It decreases hepatic glucose production, delays intestinal glucose absorption, and improves insulin sensitivity by enhancing peripheral glucose uptake and utilization.

Pioglitazone is a potent and highly selective agonist for the peroxisome proliferator-activated receptor-gamma (PPAR-gamma). Activation of these receptors promotes the production of gene products involved in lipid and glucose metabolism. It also improves insulin response to target cells without increasing the pancreatic secretion of insulin and reduces hepatic glucose production.

Use of Tri Glynase 2 mg Tablet:

Tri Glynase 2 mg tablet is prescribed for the treatment of patients with type 2 diabetes mellitus. It helps control high blood glucose levels.

Usage Direction of Tri Glynase 2 mg Tablet:

• Tri Glynase 2 mg tablet is intended for oral use only in a dose and direction as advised by the physician.
• Tri Glynase 2 mg tablet is taken whole with the help of water.
• Do not crush, chew, or break the tablet.
• Do not skip or stop the medicine without physician's advice.
• Do not consume more than the prescribed quantity.

Precaution & Related information of Tri Glynase 2 mg Tablet:

• It is dangerous to take this preparation except under medical supervision.
• If allergic to this medicine inform the physician immediately.
• If find any other complication inform the physician immediately.
• Consult with the physician during pregnancy & lactation.
• Keep out of reach of children.

Warning for products containing Pioglitazone Hydrochloride:

• The drug should not be used as first line therapy for diabetes.
• Patients with active bladder cancer or with a history of bladder cancer or those with uninvestigated haematuria should not receive pioglitazone.
• Prescribers should review the safety and efficacy of pioglitazone in individuals after 3 to 6 months of treatment to ensure that only patients who are deriving benefit continue to be treated. Pioglitazone should be stopped in patients who do not respond adequately to treatment (eg, reduction in glycosylated haemoglobin, HbA1c).
• Before starting pioglitazone, the following known risk factors for development for bladder cancer should be assessed in individuals: age, current or past history of smoking, exposure to some occupational of chemotherapy agents such as cyclophosphamide or previous irradiation of the pelvic region.
• Use in elderly patients should be considered carefully before and during treatment because of the risk of bladder cancer increases with age. Elderly patients should start on lowest possible dose and be regularly monitored because of the risks of bladder cancer and heart failure associated with pioglitazone.

Storage condition of Tri Glynase 2 mg Tablet:

Store in a cool, dry & dark place.